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SHORT COMMUNICATION
Oral contraceptives and primary liver cancer
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Several anedoctal reports (Sricker & Spoelestra, 1985),
analyses of vital statistics (Forman et al., 1983) and at least
three case-control studies conducted in California
(Henderson et al., 1983) and Britain (Forman et al., 1986;
Neuberger et al., 1986) have suggested that the risk of
hepatocellular carcinoma is increased in long-term users of
oral contraceptives (OC). This association is biologically
plausible, since the pill is known to increase substantially the
risk of adenomas of the liver (Mettlin & Natarajan, 1981),
and experimental evidence has shown that oral contra-
ceptives are effective promoters of hepatocarcinogenesis in
rodents (Yager & Yager, 1980).
In Italy, the prevalence of OC use has been traditionally
low (La Vecchia et al., 1986). However, inspection of death
certification data indicated that the rise in mortality from
liver cancer between the late 1950s and the late 1970s was
greater in females than in males below age 35, but the
opposite was true at later ages (Decarli & La Vecchia, 1984).
Although only about 10 deaths per year in Italian women
are attributed to primary liver cancer before age 35, and
fewer than 50 below age 45, this pattern of trends prompted
us to examine further the relation between oral contra-
ceptives and primary liver cancer, using data from a case-
control study conducted in Milan.
The data were derived from an ongoing case-control study
of several digestive-tract neoplasms, based on a network of
teaching and general hospitals in the greater Milan area (La
Vecchia et al., 1987). Between January 1984 and October
1987, 21 female cases of histologically or serologically con-
firmed primary liver cancer (aged 32-59, median age 50)
were interviewed using a structured questionnaire including
information on socio-demographic indicators, personal char-
acteristics and habits, selected dietary information, a
problem-oriented medical history, and history of use of oral
contraceptives and other selected drugs.
The comparison group consisted of 145 women (aged 30-
59, median age 50), admitted to a network of hospitals with
a catchment area comparable to that of cancer cases, for a
wide spectrum of acute, non-neoplastic diseases (37%
traumas, 13% other orthopaedics, 40% surgical, 10% other
miscellaneous).
Statistical analyses were based on standard methods for
case-control studies (Breslow & Day, 1980).
The major findings in relation to oral contraceptive use
are given in Table I. There were four (19.0%) cases who
had ever used OCs compared with 11 (7.6%) controls. The
Table I Relative risk of primary liver cancer in relation to use of
oral contraceptives, Milan, Italy, 1984-7
Relative
Duration of oral risk
contraceptive use Hepatocellular estimates
(years) carcinoma Controls (95% CI)
Never used 17 134 1
<5 years 2 9 1.8
(0.4 and 9.2)




aAdjusted for age in decades.
relative risk was 1.8 for up to 5 years' use, and 8.3 for over
5 years. The trend in risk was statistically significant.
Hepatitis B serum markers were not determined in this
study. A clinical history of hepatitis infection was reported
by three (14%) cases and 10 (7%) controls. One case and
two controls had evidence of liver cirrhosis. These and other
major risk factors for liver cancer in both sexes were
considered in a separate paper (La Vecchia et al., 1988).
The epidemiology of primary liver cancer in Italy differs
from that in Northern European and American countries,
Italy having a higher incidence and mortality, probably in
consequence of greater prevalence of its major risk factors,
i.e. hepatitis B virus and alcohol consumption (La Vecchia &
Decarli, 1985; La Vecchia et al., 1988). It is thus interesting
to find confirmation in this population of the association
between oral contraceptives and hepatocellular carcinoma,
although the small absolute numbers and the low prevalence
of ever users were major limitations of this study, impeding
any analysis of subgroups or interactions. The low preva-
lence of pill users even among the cases, furthermore,
indicates that, although the relative risk was significantly
elevated in long-term users, the attributable risk for oral
contraceptives is probably small in this population.
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